Shimizu H, Shimomura Y, Inukai T, Takahashi M, Uehara Y, Kobayashi I, Kobayashi S
First Department of Internal Medicine, Gunma University School of Medicine, Maebashi, Japan.
Jpn J Med. 1990 Mar-Apr;29(2):222-5. doi: 10.2169/internalmedicine1962.29.222.
The effects of intravenously administered prostaglandin E1 (PGE1) on diabetic mononeuropathy was investigated in three patients with diabetic oculomotor palsy. PGE1 (1.0-1.5 micrograms/day) was intravenously administered every morning for 4 or 6 weeks. Diplopia, blepharoptosis and decreased range of ocular movement, which were observed on admission, immediately began to improve at 1-4 days after the beginning of the treatment. On the final day of the treatment, none of the above signs remained in the three cases. The present study suggests that improvement of intraneural microcirculation by PGE1 administration results in an immediate recovery from diabetic oculomotor nerve palsy.
研究了静脉注射前列腺素E1（PGE1）对3例糖尿病性动眼神经麻痹患者糖尿病性单神经病的影响。每天早晨静脉注射PGE1（1.0 - 1.5微克），持续4或6周。入院时观察到的复视、上睑下垂和眼球活动范围减小，在治疗开始后1 - 4天立即开始改善。在治疗的最后一天，3例患者上述体征均消失。本研究表明，给予PGE1改善神经内微循环可使糖尿病性动眼神经麻痹立即恢复。
